Enovis (NYSE:ENOV) Insider Oliver Engert Purchases 2,458 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 2,458 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were bought at an average cost of $20.32 per share, for a total transaction of $49,946.56. Following the completion of the transaction, the insider owned 56,098 shares in the company, valued at approximately $1,139,911.36. This represents a 4.58% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Thursday, September 3rd, Oliver Engert bought 5,140 shares of Enovis stock. The stock was purchased at an average cost of $19.46 per share, with a total value of $100,024.40.
• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $20.92 per share, for a total transaction of $20,920.00.
• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The stock was purchased at an average price of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average cost of $23.00 per share, with a total value of $23,000.00.

Enovis Stock Down 4.2%

Shares of ENOV stock opened at $18.58 on Friday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31. Enovis Corporation has a one year low of $18.52 and a one year high of $34.28. The company’s fifty day moving average price is $25.50 and its 200-day moving average price is $24.20. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same quarter in the previous year, the company earned $0.79 EPS. Enovis’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Arax Advisory Partners purchased a new stake in shares of Enovis in the fourth quarter valued at $29,000. Allworth Financial LP purchased a new position in shares of Enovis during the 2nd quarter worth about $36,000. EverSource Wealth Advisors LLC boosted its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Public Employees Retirement System of Ohio bought a new position in Enovis during the 2nd quarter valued at about $48,000. Finally, Danske Bank A S bought a new position in Enovis during the 3rd quarter valued at about $64,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. UBS Group reiterated a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a research note on Wednesday. Evercore set a $32.00 price objective on shares of Enovis in a research report on Monday, July 6th. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, BMO Capital Markets set a $27.00 target price on shares of Enovis in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.38.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.